» Articles » PMID: 33181461

Effect of Surgical Margin on Recurrence Based on Preoperative Circulating Tumor Cell Status in Hepatocellular Carcinoma

Overview
Journal EBioMedicine
Date 2020 Nov 12
PMID 33181461
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High rates of recurrence after resection severely worsen hepatocellular carcinoma (HCC) prognosis. This study aims to explore whether circulating tumor cell (CTC) is helpful in determine the appropriate liver resection margins for HCC patients.

Methods: HCC patients who underwent liver resection were enrolled into training (n=117) or validation (n=192) cohorts, then classified as CTC-positive (CTC≥1) or CTC-negative (CTC=0). A standardized pathologic sampling method was used in the training cohort to quantify microvascular invasion (mVI) and the farthest mVI from the tumor (FMT).

Findings: CTC number positively correlated with mVI counts (r=0.655, P<0.001) and FMT (r=0.495, P<0.001). The CTC-positive group had higher mVI counts (P=0.032) and greater FMT P=0.008) than the CTC-negative group. In the CTC-positive group, surgical margins of >1 cm independently protected against early recurrence (training cohort, P=0.004; validation cohort, P=0.001) with lower early recurrence rates (training cohort, 20.0% vs. 65.1%, P=0.005; validation cohort, 36.4% vs. 65.1%, P=0.003) compared to surgical margins of ≤1 cm. No differences in postoperative liver function were observed between patients with margins >1 cm vs. ≤1 cm. Surgical margin size minimally impacted early postoperative HCC recurrence in CTC-negative patients when using 0.5 cm or 1 cm as the threshold.

Interpretations: Preoperative CTC status predicts mVI severity in HCC patients and is a potential factor for determining optimal surgical margin size to ensure disease eradication and conserve liver function. A surgical margin of >1 cm should be achieved for patients with positive CTC.

Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgement section.

Citing Articles

Histopathological diagnosis of microvascular invasion in hepatocellular carcinoma: Is it reliable?.

Li L, Wu C, Ye F, Xuan Z, Zhang X, Li J World J Gastroenterol. 2025; 31(5):98928.

PMID: 39926219 PMC: 11718611. DOI: 10.3748/wjg.v31.i5.98928.


Exploring Circulating Tumor Cells: Detection Methods and Biomarkers for Clinical Evaluation in Hepatocellular Carcinoma.

Hsu C, Liu Y, Huang J J Clin Transl Hepatol. 2024; 12(12):1020-1042.

PMID: 39649035 PMC: 11622199. DOI: 10.14218/JCTH.2024.00230.


MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.

Wang Y, Qu Y, Yang C, Wu Y, Wei H, Qin Y Eur Radiol. 2024; .

PMID: 39235653 DOI: 10.1007/s00330-024-11043-5.


Preoperative prediction of microvascular invasion risk in hepatocellular carcinoma with MRI: peritumoral versus tumor region.

Wei G, Fang G, Guo P, Fang P, Wang T, Lin K Insights Imaging. 2024; 15(1):188.

PMID: 39090456 PMC: 11294513. DOI: 10.1186/s13244-024-01760-2.


Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.

Mondal D, Shinde S, Sinha V, Dixit V, Paul S, Gupta R Front Mol Biosci. 2024; 11:1385238.

PMID: 38770216 PMC: 11103528. DOI: 10.3389/fmolb.2024.1385238.